Summit Therapeutics revenue and financials
$17.31Change from previous close: +0.23%Absolute change: +$0.04
Fiscal year ending in December. Sources and method on the page Methodology and sources.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 752 | 648 | 751 | 262 | 324 | 384 | 436 | 503 | 342 | 177 | 203 | 218 |
| Current assets | 721 | 617 | 720 | 246 | 309 | 371 | 424 | 490 | 329 | 163 | 190 | 205 |
| Cash and equivalents | 419 | 107 | 225 | 239 | 298 | 212 | 105 | 93.8 | 28.4 | 61.3 | 71.4 | 23.8 |
| Short-term investments | 271 | 492 | 488 | 0.0 | 0.0 | 150 | 307 | 393 | 297 | 95.4 | 115 | 175 |
| Receivables | — | — | — | — | — | — | — | 0.7 | 1.0 | 0.9 | 0.8 | 0.8 |
| Net property, plant and equipment | 21.2 | 21.1 | 21.7 | 6.2 | 6.2 | 7.0 | 7.4 | 8.2 | 8.9 | 9.6 | 6.1 | 6.6 |
| Goodwill | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 1.9 | 1.9 | 2.0 | 1.9 | 1.9 | 1.9 | 1.8 |
| Current liabilities | 104 | 83.3 | 73.0 | 64.9 | 60.3 | 34.9 | 41.7 | 59.0 | 140 | 23.4 | 20.4 | 114 |
| Accounts payable | 22.9 | 27.5 | 20.3 | 22.2 | 23.0 | 5.0 | 4.6 | 3.3 | 3.3 | 6.4 | 2.7 | 3.3 |
| Long-term debt | — | — | — | — | — | — | — | — | — | 100 | 100 | — |
| Total debt | 20.4 | 20.0 | 20.9 | 5.4 | 5.6 | — | — | — | — | — | — | — |
| Total liabilities | 122 | 102 | 92.3 | 69.5 | 64.6 | 39.5 | 46.8 | 64.9 | 147 | 133 | 125 | 119 |
| Total equity (incl. minority) | 630 | 546 | 659 | 192 | 259 | 344 | 389 | 438 | 195 | 44.2 | 77.7 | 99.4 |
| Retained earnings | -2,699 | -2,484 | -2,294 | -2,075 | -1,843 | -1,277 | -1,215 | -1,153 | -1,097 | -1,037 | -993 | -957 |